NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis $2.28 -0.15 (-6.17%) Closing price 03:59 PM EasternExtended Trading$2.27 -0.01 (-0.44%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About TriSalus Life Sciences Stock (NASDAQ:TLSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TriSalus Life Sciences alerts:Sign Up Key Stats Today's Range$2.17▼$2.5750-Day Range$2.30▼$5.1052-Week Range$2.17▼$7.95Volume389,909 shsAverage Volume300,557 shsMarket Capitalization$140.39 millionP/E RatioN/ADividend YieldN/APrice Target$9.20Consensus RatingModerate Buy Company Overview TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist. TriSalus became publicly traded following its 2023 business combination with MedTech Acquisition Corporation. The company is headquartered in Westminster, Colorado.AI Generated. May Contain Errors. Read More TriSalus Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreTLSI MarketRank™: 3.026786898285 of 5 starsTriSalus Life Sciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 370th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingTriSalus Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTriSalus Life Sciences has a consensus price target of $9.20, representing about 317.2% upside from its current price of $2.21.Amount of Analyst CoverageTriSalus Life Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TriSalus Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TriSalus Life Sciences are expected to grow in the coming year, from ($0.62) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TriSalus Life Sciences is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TriSalus Life Sciences is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.43% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 28.45, which indicates bearish sentiment.Change versus previous monthShort interest in TriSalus Life Sciences has recently decreased by 3.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.16 News SentimentTriSalus Life Sciences has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 27 news articles for TriSalus Life Sciences this week, compared to 3 articles on an average week. Company Ownership3.5 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $109,274.00 in company stock, which represents 0.0805% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have bought 4,008.58% more of their company's stock than they have sold. Specifically, they have bought $112,000.00 in company stock and sold $2,726.00 in company stock.Percentage Held by Insiders16.30% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLSI Stock News HeadlinesWhat is HC Wainwright's Estimate for TLSI FY2026 Earnings?November 15 at 9:59 AM | americanbankingnews.comTriSalus Life Sciences (TLSI) Stock Fair Value Moves Lower After Q3 Miss And Guidance ResetNovember 14 at 9:47 AM | finance.yahoo.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 16 at 1:00 AM | Behind the Markets (Ad)TriSalus Life Sciences (NASDAQ:TLSI) Stock Gets Price Target Trim from HC WainwrightNovember 14 at 2:31 AM | americanbankingnews.comTriSalus Life Sciences Reports Q3 Revenue Growth Of 11%; Raises $46M-$48M FY26 OutlookNovember 11, 2026 | rttnews.comTriSalus (TLSI) Q3 2026 Earnings Call TranscriptNovember 10, 2026 | finance.yahoo.comTriSalus Life Sciences Q3 2026 earnings call transcriptNovember 10, 2026 | msn.comTriSalus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10, 2026 | marketscreener.comMSee More Headlines TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed this year? TriSalus Life Sciences' stock was trading at $6.98 at the beginning of 2026. Since then, TLSI shares have decreased by 68.4% and is now trading at $2.2050. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) posted its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.02. The business had revenue of $12.88 million for the quarter, compared to analyst estimates of $14.02 million. Read the conference call transcript. Who are TriSalus Life Sciences' major shareholders? Top institutional shareholders of TriSalus Life Sciences include State Street Corp (1.09%), Nantahala Capital Management LLC (0.81%), White Pine Capital LLC (0.81%) and Royce & Associates LP (0.32%). Insiders that own company stock include Equity Ab Frankenius, Michael P Stansky, Mary T Szela, George Kelly Martin, Mats Wahlstrom, Sean Murphy, Bryan F Cox, Richard Marshak, Jodi Devlin, Gary B Gordon and James Emmett Young. View institutional ownership trends. How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TriSalus Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include Definium Therapeutics (DFTX), Palantir Technologies (PLTR), Solid Biosciences (SLDB), Cabaletta Bio (CABA), Biomea Fusion (BMEA), Amprius Technologies (AMPX) and Cameco (CCJ). Company Calendar Last Earnings11/10/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 5 days ago, TLSI's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees102Year Founded2009Price Target and Rating Average Price Target for TriSalus Life Sciences$9.20 High Price Target$12.00 Low Price Target$4.00 Potential Upside/Downside+303.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.23 million Net Margins-56.60% Pretax Margin-56.57% Return on EquityN/A Return on Assets-55.00% Debt Debt-to-Equity Ratio47.60 Current Ratio4.22 Quick Ratio3.86 Sales & Book Value Annual Sales$46.39 million Price / Sales3.03 Cash FlowN/A Price / Cash FlowN/A Book Value($0.68) per share Price / Book-3.35Miscellaneous Outstanding Shares61,575,000Free Float51,538,000Market Cap$140.39 million OptionableOptionable Beta0.50 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:TLSI) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.